Small interfering RNA to treat pancreatic cancer

DC Julien, A Giri, RA Hill

    Research output: Other contribution to conferenceAbstractpeer-review

    Abstract

    Most pancreatic cancers possess point mutations in the K-Ras oncogene. The majority of K-Ras point mutations result in K-Ras being constitutively activated leading to increased cell proliferation, growth, and inhibition of apoptotic pathways. Studies have suggested that small interfering RNA (siRNA) designed against mutated K-Ras (mK-Ras) may be a treatment option for pancreatic cancers. The aim of this study was to characterize the effects of mK-Ras siRNA on cell viability, proliferation, and metabolic activity in pancreatic cancer cell lines.
    Original languageEnglish
    Pages140
    Number of pages1
    DOIs
    Publication statusPublished - 2013
    EventWestern Regional Meeting of the American Federation for Medical Research - Carmel, United States
    Duration: 24 Jan 201326 Jan 2013
    http://afmr.org/archives/2013/Western-Regional.cgi

    Conference

    ConferenceWestern Regional Meeting of the American Federation for Medical Research
    Country/TerritoryUnited States
    CityCarmel
    Period24/01/1326/01/13
    Internet address

    Fingerprint

    Dive into the research topics of 'Small interfering RNA to treat pancreatic cancer'. Together they form a unique fingerprint.

    Cite this